The Aegis Vaccine Platform
A New Paradigm in Cross Protective Vaccines
The Aegis Vaccine Platform offers a new paradigm in cross protective vaccines. Pacific GeneTech owns the exclusive global rights against viral, bacterial and parasitic diseases in animals and humans using microbial “vectors”, including both bacteria and yeasts. Aegis utilizes recombinant technology for the insertion of bacterial, viral or protozoan genes into microbial vectors. These genes are “expressed” by the vector cell to produce specific antigens and immune enhancing proteins on the vector cell surface. Aegis vaccines use “universal” antigens which are protective across a range of pathogen strains and even species, and are manufactured using a low-cost fermentation process.
How are Aegis vaccines different from traditional vaccines?
Existing “classical” vaccines mainly offer protection against specific pathogen strains used to make the vaccines. There is often little cross protection against other strains and protection against genetic changes or mutations is minimal. Aegis vaccines offer broad spectrum cross protection, reducing or eliminating the need for multiple vaccines, and they address the problem of mutation. Traditionally, inactivated vaccines are only effective as injectables, are labour intensive and costly to administer. Aegis vaccines can be delivered live or inactivated, and orally via water or spray.
Hercules Adjuvant System
A Novel Universal Adjuvant Delivery System
Hercules is a modified Chitosan adjuvant that enhances immune response to multiple antigens, including orally administered antigens.
Hercules when used orally promotes secretory immunoglobulin A (sIgA) on mucous membranes, inhibiting pathogen invasion at the site of attack, and is effective even with inactivated vaccines. Historically, orally delivered vaccines have tended to be live.
Pacific GeneTech holds the global, exclusive rights to Hercules and it is the adjuvant for all inactivated vaccines in development based on the Aegis platform. Hercules is available for partnering and out-licensing opportunities, particularly with vaccine manufacturers seeking to apply previously injectable vaccines orally.
Pacific GeneTech’s lead vaccines initially targeted animal pathogens. Our Salmonella and E. coli vaccine for poultry is under evaluation by USDA and expected to launch in 2021 in the United States. We are also testing this vaccine for possible protection against Campylobacter. In 2019 we submitted an application to USDA for our inactivated poultry Eimeria vaccine.
Salmonella and E. coli are also major pathogens in other animals, including pigs and ruminants and, of course, humans. Eimeria is a protozoan apicomplexan parasite also related to other apicomplexa, including Toxoplasma, Cryptosporidium and Plasmodium, the malarial parasite. Like Salmonella and E. coli, Toxoplasma and Cryptosporidium are typical zoonotic diseases and are found in both animals and humans, while malaria is primarily a human disease. Pacific GeneTech has ongoing programs for these pathogens for both veterinary and human applications.
For more details on our other vaccines under development, please refer to our Pipeline Chart.